CA2538159A1 - Polyamine-metal chelator conjugates - Google Patents

Polyamine-metal chelator conjugates Download PDF

Info

Publication number
CA2538159A1
CA2538159A1 CA002538159A CA2538159A CA2538159A1 CA 2538159 A1 CA2538159 A1 CA 2538159A1 CA 002538159 A CA002538159 A CA 002538159A CA 2538159 A CA2538159 A CA 2538159A CA 2538159 A1 CA2538159 A1 CA 2538159A1
Authority
CA
Canada
Prior art keywords
moiety
group
substituted
compound
polyamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002538159A
Other languages
English (en)
French (fr)
Inventor
Raymond J. Bergeron, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2538159A1 publication Critical patent/CA2538159A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CA002538159A 2003-09-09 2004-09-09 Polyamine-metal chelator conjugates Abandoned CA2538159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50134103P 2003-09-09 2003-09-09
US60/501,341 2003-09-09
PCT/US2004/029318 WO2005023310A2 (en) 2003-09-09 2004-09-09 Polyamine-metal chelator conjugates

Publications (1)

Publication Number Publication Date
CA2538159A1 true CA2538159A1 (en) 2005-03-17

Family

ID=34273034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002538159A Abandoned CA2538159A1 (en) 2003-09-09 2004-09-09 Polyamine-metal chelator conjugates

Country Status (8)

Country Link
US (1) US20080096974A2 (enExample)
EP (1) EP1667727B1 (enExample)
JP (1) JP2007505044A (enExample)
AT (1) ATE400300T1 (enExample)
AU (1) AU2004270261B2 (enExample)
CA (1) CA2538159A1 (enExample)
DE (1) DE602004014949D1 (enExample)
WO (1) WO2005023310A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
PL1866296T3 (pl) * 2005-04-04 2017-05-31 University Of Florida Research Foundation, Inc. Polieterowe analogi desferritiocyny
EP2065057A3 (en) * 2006-03-15 2009-08-12 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
WO2008130395A2 (en) * 2006-12-12 2008-10-30 University Of Florida Desferrithiocin analogue actinide decorporation agents
CA2680592C (en) 2007-03-15 2016-07-05 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
WO2009055863A1 (en) 2007-11-01 2009-05-07 The University Of Sydney Desferrioxamine conjugates, derivatives and analogues
JP5431361B2 (ja) * 2008-01-09 2014-03-05 セルカ ゲーエムベーハー 改善された培養培地添加物及びそれを用いる方法
US7932326B2 (en) * 2008-04-16 2011-04-26 The University Of Kentucky Research Foundation Chelating compounds and immobilized tethered chelators
US9259670B2 (en) 2008-04-16 2016-02-16 The University Of Kentucky Research Foundation Flow-through filter to remove aluminum from medical solutions
WO2010009120A2 (en) 2008-07-14 2010-01-21 Ferrokin Biosciences, Inc. Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
JP2013525268A (ja) 2010-03-02 2013-06-20 ユニバーシティ・オブ・カンザス 鉄キレーターとしてのポリアミン−ジヒドロキシ安息香酸結合体ヒドロゲル
CA2798082A1 (en) 2010-05-04 2011-11-10 Shire Llc Desazadesferrothiocin analogues as metal chelation agents
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
FR2984317B1 (fr) 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
EP3448378B1 (en) * 2016-04-29 2024-04-17 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
WO2020092464A1 (en) 2018-10-30 2020-05-07 The Research Foundation For The State University Of New York Compositions and methods for removal of negatively charged impurities using metal-cellulose fiber composite

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091576A (en) * 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US6184232B1 (en) * 1986-12-02 2001-02-06 University Of Florida Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
US5342945A (en) * 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
FI940833A7 (fi) * 1991-08-23 1994-02-22 Pfizer Eksitatoristen aminohapponeurotransmittereiden antagonisteina käyttöke lpoisia synteettisiä aryylipolyamiineja
US5493053A (en) * 1994-12-21 1996-02-20 University Of Florida Research Foundation, Inc. Method for preparing desferrioxamine B and homologs thereof
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
US5739395A (en) * 1997-01-10 1998-04-14 University Of Florida Research Foundation, Inc. Method for synthesis of rhizoferrin
ES2244042T3 (es) * 1997-01-21 2005-12-01 Ge Healthcare Limited Sustratos del factor xiiia marcados.
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin

Also Published As

Publication number Publication date
JP2007505044A (ja) 2007-03-08
DE602004014949D1 (de) 2008-08-21
WO2005023310A3 (en) 2005-04-21
AU2004270261B2 (en) 2008-12-04
AU2004270261A1 (en) 2005-03-17
US20080096974A2 (en) 2008-04-24
WO2005023310A2 (en) 2005-03-17
EP1667727A2 (en) 2006-06-14
ATE400300T1 (de) 2008-07-15
EP1667727B1 (en) 2008-07-09
US20060211773A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
AU2004270261B2 (en) Polyamine-metal chelator conjugates
Liu et al. Design of iron chelators with therapeutic application
Hegetschweiler A rigid, cyclohexane-based polyamino-polyalcohol as a versatile building block for tailored chelating agents
US20220041608A1 (en) Radiopharmaceuticals, radioimaging agents, and uses thereof
JP2659351B2 (ja) 金属キレート−蛋白質複合体を形成するための多置換ジエチレントリアミンおよびその製造方法
US9687572B2 (en) PSMA-targeted dendrimers
EP2813223B1 (en) Metal delivery agents and terapeutic uses of the same
US10842893B2 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
JPS62502618A (ja) 金属キレ−トたんぱく質接合体の形成方法
JP2023184620A (ja) ポリペプチドを修飾するための組成物及び方法
JP6944720B2 (ja) リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体
Santos et al. Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: Synthesis, complexation with Fe (III), Al (III) and Ga (III) and in vivo evaluation with 67Ga
JP7646637B2 (ja) 画像化及び治療用組成物
CA2767339C (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
US20140364454A1 (en) Metal-chelating compounds having at least one polyamino chain
WO2006086773A2 (en) Polyamine analogs as modulators of cell migration and cell motility
US20230031576A1 (en) Radiolabelled targeting ligands
Gateau et al. Rational Design of Copper and Iron Chelators to Treat Wilson's Disease and Hemochromatosis
WO2023092184A1 (en) Compounds and compositions thereof for the treatment of cancer
Burke The Synthesis and Biological Activity of Iron Binding Motifs
JP2019535823A (ja) 化学療法で誘発されたｐｓｎを防止および処置するための非遷移金属配位ジピリドキシル化合物の使用
HK1224924A1 (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
HK1171367A (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued